Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Revenue (2018 - 2026)

Catalyst Pharmaceuticals filings provide 9 years of Revenue readings, the most recent being $149.4 million for Q1 2026.

  • On a quarterly basis, Revenue rose 5.63% to $149.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $597.0 million, a 11.65% increase, with the full-year FY2025 number at $589.0 million, up 19.78% from a year prior.
  • Revenue hit $149.4 million in Q1 2026 for Catalyst Pharmaceuticals, down from $152.6 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $152.6 million in Q4 2025 to a low of $43.1 million in Q1 2022.
  • Median Revenue over the past 5 years was $110.6 million (2023), compared with a mean of $108.4 million.
  • Biggest five-year swings in Revenue: soared 98.12% in 2023 and later increased 5.63% in 2026.
  • Catalyst Pharmaceuticals' Revenue stood at $60.8 million in 2022, then surged by 81.98% to $110.6 million in 2023, then increased by 28.26% to $141.8 million in 2024, then grew by 7.61% to $152.6 million in 2025, then decreased by 2.11% to $149.4 million in 2026.
  • The last three reported values for Revenue were $149.4 million (Q1 2026), $152.6 million (Q4 2025), and $148.4 million (Q3 2025) per Business Quant data.